Feb 16, 2022 | Press Releases
Tampa INVO Center to focus on advanced fertility care utilizing INVOcell®SARASOTA, Fla. and TAMPA, Fla., Feb. 16, 2022 — INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide...
Feb 9, 2022 | Press Releases
SAN FRANCISCO, CA / February 9, 2022 / Today, the global fertility market is a multi-billion industry, yet remains severely underserved, with estimates suggesting more than 90% of couples in need of infertility treatment going without care. INVO Bioscience...
Feb 3, 2022 | Press Releases
Focused on addressing underserved patients within the fertility marketplaceSARASOTA, Fla., Feb. 3, 2022 — INVO Bioscience, Inc. (NASDAQ: INVO) (“Company”) (“INVO”), a commercial-stage fertility company focused on expanding access to...
Dec 16, 2021 | Press Releases
Agreement follows initial utilization of INVOcell by Ovoclinic phyisicians in early 2021, resulting in successful patient experiences and outcomesOvoclinic will expand use of INVOcell in all four of their clinics and become the Center of Excellence and Training Site...
Dec 10, 2021 | Press Releases
SARASOTA, Fla., Dec. 10, 2021 — INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo culture system (IVC), INVOcell®, announced today that it will be participating in the Lytham Partners...
